Krueger Kimberly, Mayer Zsuzsanna, Kottmaier Marc, Gerckens Miriam, Boeck Stefan, Luppa Peter, Holdenrieder Stefan
German Heart Center Munich, Clinics at the Technical University Munich, Institute of Laboratory Medicine, Munich Biomarker Research Center, 80636 Munich, Germany.
German Heart Center Munich, Clinics at the Technical University Munich, Department of Cardiovascular Disease, 80636 Munich, Germany.
Biomedicines. 2022 Oct 11;10(10):2534. doi: 10.3390/biomedicines10102534.
The interaction between programmed death-1 receptor PD-1 and its ligands PD-L1 and PD-L2 is involved in self-tolerance, immune escape of cancer, cardiovascular diseases, and COVID-19. As blood-based protein markers they bear great potential to improve oncoimmunology research and monitoring of anti-cancer immunotherapy. A variety of preanalytical conditions were tested to assure high quality plasma sample measurements: (i) different time intervals and storage temperatures before and after blood centrifugation; (ii) fresh samples and repeated freeze-thaw-cycles; (iii) different conditions of sample preparation before measurement. Concerning short-term stability, acceptable recoveries for PD-1 between 80 and 120% were obtained when samples were kept up to 24 h at 4 and 25 °C before and after blood centrifugation. Similarly, recoveries for PD-L2 were acceptable for 24 h at 4 °C and 6 h at 25 °C before blood centrifugation and up to 24 h at 4 and 25 °C after centrifugation. Variations for PD-L1 were somewhat higher, however, at very low signal levels. Sample concentrations (ng/mL) were neither affected by the freezing process nor by repeated freeze-thaw cycles with coefficients of variation for PD-1: 9.1%, PD-L1 6.8%, and PD-L2 4.8%. All three biomarkers showed good stability regarding preanalytic conditions of sample handling enabling reliable and reproducible quantification in oncoimmunology research and clinical settings of anti-cancer immunotherapy.
程序性死亡-1受体(PD-1)与其配体PD-L1和PD-L2之间的相互作用参与了自身耐受性、癌症免疫逃逸、心血管疾病以及新型冠状病毒肺炎(COVID-19)。作为血液中的蛋白质标志物,它们在改善肿瘤免疫研究和抗癌免疫治疗监测方面具有巨大潜力。为确保高质量的血浆样本测量,测试了多种分析前条件:(i)血液离心前后的不同时间间隔和储存温度;(ii)新鲜样本和反复冻融循环;(iii)测量前不同的样本制备条件。关于短期稳定性,在血液离心前后,样本在4℃和25℃下保存长达24小时时,PD-1的回收率在80%至120%之间,可接受。同样,在血液离心前,PD-L2在4℃下24小时和25℃下6小时的回收率可接受,离心后在4℃和25℃下长达24小时也可接受。然而,在非常低的信号水平下,PD-L1的变化略高。样本浓度(ng/mL)既不受冷冻过程的影响,也不受反复冻融循环的影响,PD-1、PD-L1和PD-L2的变异系数分别为9.1%、6.8%和4.8%。在肿瘤免疫研究和抗癌免疫治疗的临床环境中,所有这三种生物标志物在样本处理的分析前条件方面均表现出良好的稳定性,能够实现可靠且可重复的定量分析。